# Switch to Oral Antibiotics in Gram-negative Bacteremia

> **NCT04146922** · NA · COMPLETED · sponsor: **Hamad Medical Corporation** · enrollment: 176 (actual)

## Conditions studied

- Escherichia Coli Bacteremia
- Klebsiella Bacteraemia
- Enterobacter Bacteraemia
- Serratia Bacteraemia
- Citrobacter Bacteraemia
- Proteus Bacteraemia

## Interventions

- **OTHER:** Step down to oral antimicrobial therapy
- **OTHER:** IV antimicrobial therapy

## Key facts

- **NCT ID:** NCT04146922
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-13
- **Primary completion:** 2022-08-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04146922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04146922, "Switch to Oral Antibiotics in Gram-negative Bacteremia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04146922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*